A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Latest Information Update: 31 Jan 2025
Price :
$35 *
At a glance
- Drugs CC 94676 (Primary) ; Abiraterone; Docetaxel; Enzalutamide; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms rechARge
- Sponsors Celgene Corporation
- 13 Jan 2025 New trial record